New hope for leukemia patients: experimental drug combo enters late-stage trial
NCT ID NCT07255872
First seen Dec 10, 2025 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests a new drug called BL-M11D1 combined with either standard chemotherapy (cytarabine + daunorubicin) or targeted therapy (venetoclax + azacitidine) for adults newly diagnosed with acute myeloid leukemia. The goal is to see if the combination is safe and works better than current treatments. About 216 participants will take part across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.